HF
ARTV

HRT Financial’s Artiva Biotherapeutics ARTV Stock Holding History

HRT Financial’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-26,953
Closed -$77K – 4233
2025
Q3 		$77K Sell
26,953
-50,703
-65% -$136K ﹤0.01% 2553
2025
Q2 		$117K Buy
+77,656
New +$163K ﹤0.01% 2183

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HRT Financial's ARTV Position: Q4 2025 in Review

HRT Financial sold out of Artiva Biotherapeutics (ARTV) in Q4 2025, closing a stake of 26,953 shares — an estimated $77K sold.

HRT Financial first reported a position in ARTV in Q2 2025 and held it in 2 quarters. The position peaked at $117K in Q2 2025. 34 funds tracked by Wall St. Rank hold ARTV as of Q4 2025.

  • HRT Financial reported no remaining Artiva Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 26,953 Artiva Biotherapeutics shares in Q4 2025, an estimated $77K.
  • HRT Financial first reported a position in Artiva Biotherapeutics in Q2 2025 and held it in 2 quarters.
  • HRT Financial's Artiva Biotherapeutics position peaked at $117K in Q2 2025.
  • 34 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.